Press Releases
The Implantable Cell Therapy AVB-114 Demonstrated Favorable Safety and Effectiveness in the Phase II Trial for Crohn’s Perianal Fistulas – Excerpt from the Press Release: NEWARK, Del., Oct. 29, 2025 /PRNewswire/ — Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced that the STOMP2 primary analysis results were revealed today at a…
Read More
Favorable early safety profile with preliminary clinical and mechanistic evidence of therapeutic activity in refractory rheumatoid arthritis Data to be presented in a late-breaking oral presentation today 8:00 a.m. CT at the 2025 American College of Rheumatology (ACR) Convergence Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. & SEATTLE–(BUSINESS WIRE)–Sonoma Biotherapeutics, Inc., a clinical-stage…
Read More
Excerpt from the Press Release: WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH‑HFrEF. The topline data showed that a single intravenous dose…
Read More
The next 6 months of scientific studies to investigate the utility in early stage, premalignant lesions of Toragen’s first-in-class small molecule, oral drug candidate TGN-S15 is funded by the Gates Foundation. Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., an oncology biopharmaceutical company focused on the development of TGN-S15, their oral, small molecule drug…
Read More
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in…
Read More
CuraAX aims to address debilitating blood pressure drops and cognitive symptoms of nOH Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056) in a Phase 2a proof-of-concept trial…
Read More
The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing advancement into Cohort 4 with a dose of 10 ug/kg/day Actively screening patients for Cohort 4; anticipate initiation of dosing in the coming weeks Cohort 4 dose is potentially more reflective of the clinical efficacy…
Read More
Excerpt from the Press Release: TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that its manuscript describing the discovery and preclinical development of HCB101, an engineered SIRPα-Fc fusion protein, has been published in the Journal of Hematology & Oncology…
Read More
No targeted treatments are currently FDA approved for high-grade IDH1-mutant gliomas After a favorable meeting with FDA, protocol amendment will make G203 a Phase 3 trial to support potential registration Excerpt from the Press Release: NEW YORK–(BUSINESS WIRE)– Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges…
Read More
Excerpt from the Press Release: SAN CARLOS, Calif. and DALLAS, Oct. 23, 2025 /PRNewswire/ — CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial evaluating its proprietary DNA Aptamer therapy, CGB-600, for the treatment of vitiligo. The investigational active…
Read More